Hepion pharmaceuticals initiates wind-down activities in phase 2b ‘ascend-nash' trial

Edison, n.j., april 19, 2024 (globe newswire) -- hepion pharmaceuticals, inc. (nasdaq:hepa), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis (“nash”), hepatocellular carcinoma (“hcc”), and other chronic liver diseases, today announced that it has begun wind-down activities in its ascend-nash trial, while continuing to explore strategic alternatives, as previously announced in december 2023.
HEPA Ratings Summary
HEPA Quant Ranking